구독하기
연구 모델
서비스
전임상 효능 평가
Resource
B6-hNLRP3 Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
B6-hNLRP3 Mouse
제품명
B6-hNLRP3 Mouse
제품 ID
C001616
품종 계통
C57BL/6NCya-Nlrp3tm1(hNLRP3)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “B6-hNLRP3 Mouse (카탈로그 번호 C001616)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
기본 정보
검증 데이터
관련 자료
기본 정보
유전자명
유전자 별칭
AII, AVP, FCU, MWS, FCAS, KEFH, CIAS1, FCAS1, NALP3, C1orf7, CLR1.1, DFNA34, PYPAF1, AGTAVPRL
NCBI ID
염색체
Chr 1
MGI ID
Datasheet
품종 계통 설명
The Cryopyrin protein, encoded by the NOD-like receptor family pyrin domain-containing 3 (NLRP3) gene, is a core component of the inflammasome in the innate immune system. As a member of the NOD-like receptor (NLR) family, NLRP3 is predominantly expressed in leukocytes and chondrocytes. It participates in the host defense against damage and infection by recognizing pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) to activate immune responses [1]. In its inactive monomeric state, NLRP3 senses intracellular damage signals, such as abnormal protein aggregates and lipid accumulation. Upon activation, NLRP3 oligomerizes, adopting an active conformation and assembling into inflammasome complexes, subsequently activating Caspase-1 to drive the maturation and secretion of pro-inflammatory cytokines, including IL-1β and IL-18 [1-2]. Activated NLRP3 not only induces the release of inflammatory cytokines but also triggers lytic cell pyroptosis. The intracellular components released during pyroptosis can further amplify inflammatory signals, forming a positive feedback loop of autoinflammation. Moreover, IL-1β can exacerbate the inflammatory cascade by stimulating the production of inflammatory markers such as IL-6 and high-sensitivity C-reactive protein (hsCRP) [3-4]. Given NLRP3's upstream position relative to IL-1β/IL-18 and other inflammatory factors, targeting its activity can effectively block the self-reinforcing mechanism of chronic inflammation, providing a significant therapeutic strategy for inflammation-related diseases [5]. The potential therapeutic areas include Alzheimer’s disease, Parkinson’s disease (via neuroinflammation modulation), inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis (MASH), gout, and obesity-related metabolic inflammation [6-7].
The B6-hNLRP3 mouse model was generated by replacing the mouse Nlrp3 genomic region (from the ATG start codon to downstream of the 3'UTR) with the human NLRP3 sequence (from upstream of the ATG start codon to downstream of the 3'UTR), enabling stable expression of human NLRP3 protein. The B6-hNLRP3 mouse is suitable for studying inflammatory mechanisms, autoimmune diseases, neurodegenerative diseases, and metabolic diseases. It also serves as an ideal tool for human NLRP3-targeted drug development and preclinical efficacy evaluation.
Reference
Xu J, Núñez G. The NLRP3 inflammasome: activation and regulation. Trends Biochem Sci. 2023 Apr;48(4):331-344.
Moretti J, Blander JM. Increasing complexity of NLRP3 inflammasome regulation. J Leukoc Biol. 2021 Mar;109(3):561-571.
Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010 Feb;10(2):89-102.
Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol. 2019 Apr;39(3):277-286.
Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019 Aug;19(8):477-489.
Yao J, Sterling K, Wang Z, Zhang Y, Song W. The role of inflammasomes in human diseases and their potential as therapeutic targets. Signal Transduct Target Ther. 2024 Jan 5;9(1):10.
Ma Q. Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction. Pharmacol Rev. 2023 May;75(3):487-520.
변형 전략
The mouse Nlrp3 locus (ATG start codon to downstream of the 3'UTR) was replaced with the human NLRP3 sequence (upstream of ATG to downstream of the 3'UTR) via gene editing technology.

Figure 1. Gene editing strategy of B6-hNLRP3 mice.
응용 분야
Studies of the immune system and inflammasome activation mechanisms;
Pathological mechanism analysis of cryopyrin-associated periodic syndromes (CAPS);
Development, screening, and preclinical pharmacodynamic evaluation of NLRP3-targeted drugs;
Neuroinflammation modulation research in neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease);
Exploration of mechanisms in metabolic diseases and autoimmune diseases.
검증 데이터
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
